• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Did Frontline Lymphoma Trial Success Just Shift AbbVie (ABBV) Stock Narrative?

    Simply Wall St·10/06/2026 12:19:39
    Listen to the news
    • Genmab and AbbVie reported that the Phase 3 EPCORE DLBCL-2 trial in newly diagnosed higher risk diffuse large B-cell lymphoma showed a 51% reduction in the risk of progression or death for patients receiving fixed duration subcutaneous epcoritamab plus R-CHOP versus R-CHOP alone, with a safety profile aligned to the known profiles of the individual drugs.
    • The positive readout gives AbbVie a potential new frontline lymphoma regimen in partnership with Genmab. This could deepen its oncology presence alongside existing immunology and neuroscience franchises and help address the long running need to refresh revenue as older therapies face competitive pressure.
    • We will look at how AbbVie’s investment narrative is affected by a 51% progression risk reduction in frontline DLBCL treatment.

    Scan how AbbVie’s oncology news compares with other potential breakout opportunities across 27 high quality undervalued stocks with solid cash flows and balance sheets.

    AbbVie Investment Narrative Recap

    To own AbbVie, you need to believe the post Humira rebuild can hold together, with immunology, oncology and neuroscience carrying more of the load while pricing and patent headwinds keep biting. The key short term swing factor is still execution on this broader portfolio as earnings are forecast to grow faster than the US market.

    The biggest near term risk remains pricing pressure and competition eroding returns on major drugs, especially as AbbVie carries high debt and negative equity with a dividend that is not well covered by earnings. The recent epcoritamab DLBCL data is promising clinically but does not yet change those top level pressures.

    Among the recent updates, the JUVMO approval in Parkinson’s disease is most relevant to the current epcoritamab story because it underlines the same core belief investors need in AbbVie. The business is trying to replace concentrated older revenue with multiple new therapies across oncology and neuroscience that share similar execution and uptake questions.

    JUVMO gives AbbVie an additional neurology option alongside assets like Vraylar and Vyalev, which analysts already treat as important to future neuroscience revenue. For a shareholder, the key question is whether launches such as JUVMO and potential future indications for epcoritamab arrive at enough scale and at acceptable pricing to offset ongoing loss of exclusivity and policy driven reimbursement pressure.

    What The Consensus Numbers Assume For AbbVie

    AbbVie's current analyst framework leans heavily on a steady build in the top line while newer therapies gain traction. The consensus view assumes revenue grows by 8.2% a year over the next three years, with profit margins moving from 9.7% today to 29.8% by 2029. On earnings, forecasts point to US$24.3b in 2029 compared with US$6.3b today, which implies roughly a 4x increase in profit if those estimates are met. The same set of projections has earnings per share at US$13.85 and uses a 2029 P/E of 25.4x, down from 74.4x currently, with analysts also assuming the share count stays broadly flat.

    AbbVie's narrative projects US$81.5b revenue and US$24.3b earnings by 2029. This requires 8.2% yearly revenue growth and roughly a 4x earnings increase from US$6.3b today.

    Uncover why AbbVie's fair value indicates a 5% potential upside to its current price that may not last much longer.

    NYSE:ABBV 1-Year Stock Price Chart
    NYSE:ABBV 1-Year Stock Price Chart

    Exploring Other Perspectives

    Three fair value estimates from the Simply Wall St Community span roughly US$279 to US$442 per AbbVie share, which is a wide spread for one ticker. That gap shows how differently private investors read the same oncology, immunology and neuroscience news. Consider ongoing patent and pricing risks, and explore several alternative viewpoints before deciding how AbbVie fits your portfolio.

    Explore 2 other AbbVie fair value estimates, including one that suggests as much as 66% potential increase from the current price.

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Investment Ideas Beyond AbbVie?

    If AbbVie sits near the top of your watchlist, it can still pay to widen the opportunity set and compare this story with other strong fundamentals across the market. The Simply Wall St Screener lets you filter for the kind of balance sheet quality, income profile, or risk level that best matches your goals, so you can pressure test any single stock against a broader bench of candidates.

    • If capital preservation is front of mind, start with sturdier businesses by scanning a 31 resilient stocks with low risk scores that aims to keep potential drawdowns more controlled.
    • If dependable income matters most, look for payout strength and resilience by reviewing a hand picked 7 dividend fortresses that may suit a more yield focused approach.
    • If you want quality without overpaying, compare AbbVie with a 19 high quality undiscovered gems that combine solid fundamentals with less attention from the crowd.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.